Mebendazole
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Anti-worming agent of a broad spectrum; most effective in enterobiasis. It causes an irreversible violation of glucose utilization in the body of the helminth and inhibits the synthesis of ATP.
Indications
Enterobiosis, ascariasis, ankilostomidoz, strongyloidosis, trichocephalosis, trichinosis, teniasis, echinococcosis, alveococcosis, capillariosis, gnatostomosis, mixed helminthiasis.
Composition
One tablet Wormin®a:
- 0.1 g of mebendazole.
Auxiliary components:
- Calcium phosphate;
- Magnesium stearate;
- Sodium lauryl sulfate;
- Food Color Sunset orange;
- Starch;
- Gelatin;
- Talc;
- Food Color Sunset yellow;
- Vanillin.
Mebendazole is marketed under different brands and generic names, and comes in different dosage forms:
Brand name | Manufacturer | Country | Dosage form |
---|---|---|---|
Wormin® | Cadilla | India | pills |
Vermox | Gedeon Richter | Hungary | pills |
No customer reviews for the moment.
Dosage and Administration
Adults and children over 10 years old with enterobiasis - at a dose of 100 mg once.
Children aged 2 to 10 years - at a dose of 25-50 mg once. In the case of a high likelihood of re-invasion, repeat administration after 2-4 weeks at the same dose.
It is recommended that simultaneous treatment of all family members.
In case of ascariasis, trichocephalosis, ankilostomidosis, teniosis, strongyloidosis and mixed helminthiases - 100 mg in the morning and evening for 3 days. With trichinosis - 200-400 mg 3 times / day for 3 days, and from the 4th to the 10th day - 400-500 mg 3 times / day. When echinococcosis - 500 mg 2 times / day for the first 3 days, then at the same dose 3 times / day for the next 3 days. In the future, use a dose of 25-30 mg / kg / day in 3-4 doses.
Adverse reactions
On the part of the digestive system: rarely - nausea, abdominal pain; when used in high doses for a long time, vomiting, diarrhea, transient increase in the activity of hepatic transaminases in serum are possible.
From the side of the central nervous system: rarely - dizziness; when used in high doses for a long time, headache.
On the part of the blood system: when used in high doses for a long time, leukopenia, anemia, and eosinophilia are possible.
From the urinary system: when used in high doses for a long time - hematuria, cylindruria.
Other: when used in high doses for a long time - allergic reactions, hair loss.
Contraindications
Severe liver dysfunction, pregnancy, lactation (breastfeeding), children under 2 years old, hypersensitivity to mebendazole.
Drug interactions
Mebendazole reduces the need for insulin in diabetic patients.
Co-administration of mebendazole with lipophilic substances should be avoided. With the simultaneous use of cimetidine can increase, and carbamazepine and other inducers of metabolism - reduce the concentration of mebendazole in the blood.
Pregnancy and Lactation
Contraindicated for use in pregnancy and lactation (breastfeeding).
Special instructions
With prolonged use, it is necessary to control the picture of peripheral blood, liver and kidney function.
During the day after taking mebendazole to prevent the use of alcohol.
Do not use laxative after taking mebendazole.
Periodic examination of smears of the anal area and feces is necessary after the end of treatment (therapy is considered effective in the absence of worms or their eggs for 7 consecutive days).
- Brand name: Wormin
- Active ingredient: Mebendazole
- Dosage form: pills
- Manufacturer: Cadila
Studies and clinical trials of Mebendazole (Click to expand)
- Maxitrol-induced corneal melts after routine cataract surgery in rheumatology patients
- High-pressure liquid-chromatographic determination of the anthelmintic drug mebendazole in plasma
- Synthesis and purification of [4′-3H]-mebendazole
- Synthesis and characterization of a new mebendazole salt: Mebendazole hydrochloride
- Intermolecular contacts influencing the conformational and geometric features of the pharmaceutically preferred mebendazole polymorph C
- Characterization of polymorph transformations that decrease the stability of tablets containing the WHO essential drug mebendazole
- Crystal structure determination of mebendazole form A using high-resolution synchrotron x-ray powder diffraction data
- High-performance liquid chromatographic assay for the anthelmintic agent mebendazole in human plasma
- Polymorphism incidence in commercial tablets of mebendazole: a vibrational spectroscopy investigation
- Capillary electrophoresis evidence of the stereoselective ketoreduction of mebendazole and aminomebendazole in echinococcosis patients
- Fluorimetric determination of mebendazole and flubendazole in pharmaceutical dosage forms after alkaline hydrolysis
- Determination of mebendazole in urine by cathodic stripping voltammetry
- The combined treatment with levamisole and mebendazole for a perstans-like filarial infection in Rhodesia
- Levamisole compared to mebendazole in the treatment of Ancylostoma duodenale in Egypt
- Antifilarial activity of mebendazole and flubendazole on Breinlia booliati
- Treatment of proliferative sparganosis with mebendazole and praziquantel
- Studies on the experimental chemotherapy of Angiostrongylus malaysiensis infection in rats with mebendazole and levamisole
- Experience with mebendazole in the treatment of inoperable hydatid disease in England
- Bioavailability and tolerability of mebendazole in patients with inoperable hydatid disease
- Treatment of Dipetalonema perstans infections with mebendazole
- The treatment of Fasciolopsis buski infection in children: a comparison of thiabendazole, mebendazole, levamisole, pyrantel pamoate, hexylresorcinol and tetrachloroethylene
- Mebendazole in the treatment of Schistosoma haematobium
- A comparison of the effects of albendazole, its sulphone metabolite, and mebendazole on the viability of protoscoleces of Echinococcus granulosus in an in vitro culture system
- Failure of high dose mebendazole as a microfilaricide in patients with loiasis
- Mebendazole in the treatment of mice experimentally infected with Schistosoma mansoni